Abeona Therapeutics Stock Performance
| ABEO Stock | USD 5.33 0.17 3.09% |
The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Abeona Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Abeona Therapeutics is expected to be smaller as well. At this point, Abeona Therapeutics has a negative expected return of -0.28%. Please make sure to confirm Abeona Therapeutics' value at risk, and the relationship between the jensen alpha and accumulation distribution , to decide if Abeona Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Abeona Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (3.09) | Five Day Return (9.04) | Year To Date Return (9.81) | Ten Year Return (93.17) | All Time Return (100.00) |
Last Split Factor 1:25 | Last Split Date 2022-07-05 |
1 | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | 12/02/2024 |
2 | Disposition of 4000 shares by Alvino Mark of Abeona Therapeutics at 5.1 subject to Rule 16b-3 | 01/21/2025 |
3 | Insider Sell Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc | 01/22/2025 |
4 | Disposition of 4000 shares by Alvino Mark of Abeona Therapeutics at 5.38 subject to Rule 16b-3 | 01/29/2025 |
5 | Acquisition by Alvino Mark of 36101 shares of Abeona Therapeutics subject to Rule 16b-3 | 01/31/2025 |
6 | Rosalind Advisors, Inc. Increases Stake in Cellectar Biosciences Inc | 02/04/2025 |
7 | Acquisition by Omalley Brendan M. of 5869 shares of Abeona Therapeutics at 3.13 subject to Rule 16b-3 | 02/06/2025 |
8 | abrdn plc Has 1.25 Million Holdings in Abeona Therapeutics Inc - MarketBeat | 02/14/2025 |
9 | Disposition of 18798 shares by Seshadri Vishwas of Abeona Therapeutics at 5.89 subject to Rule 16b-3 | 02/19/2025 |
10 | Abeona Therapeutics Cut to Sell at StockNews.com | 02/25/2025 |
| Begin Period Cash Flow | 14.6 M |
Abeona |
Abeona Therapeutics Relative Risk vs. Return Landscape
If you would invest 639.00 in Abeona Therapeutics on November 28, 2024 and sell it today you would lose (106.00) from holding Abeona Therapeutics or give up 16.59% of portfolio value over 90 days. Abeona Therapeutics is currently does not generate positive expected returns and assumes 2.6487% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Abeona, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Abeona Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abeona Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abeona Therapeutics, and traders can use it to determine the average amount a Abeona Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1047
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABEO |
Estimated Market Risk
| 2.65 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Abeona Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abeona Therapeutics by adding Abeona Therapeutics to a well-diversified portfolio.
Abeona Therapeutics Fundamentals Growth
Abeona Stock prices reflect investors' perceptions of the future prospects and financial health of Abeona Therapeutics, and Abeona Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abeona Stock performance.
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 145.11 M | ||||
| Shares Outstanding | 43.59 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 5.06 X | ||||
| Price To Sales | 61.63 X | ||||
| Revenue | 3.5 M | ||||
| Gross Profit | (31.4 M) | ||||
| EBITDA | (50.57 M) | ||||
| Net Income | (54.19 M) | ||||
| Cash And Equivalents | 20.1 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 5.4 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (37.01 M) | ||||
| Earnings Per Share | (2.05) X | ||||
| Market Capitalization | 232.35 M | ||||
| Total Asset | 64 M | ||||
| Retained Earnings | (749.52 M) | ||||
| Working Capital | 42.31 M | ||||
| Current Asset | 31.95 M | ||||
| Current Liabilities | 6.51 M | ||||
About Abeona Therapeutics Performance
By examining Abeona Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Abeona Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Abeona Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 304.99 | 487.59 | |
| Return On Tangible Assets | (0.76) | (0.80) | |
| Return On Capital Employed | (0.84) | (0.80) | |
| Return On Assets | (0.76) | (0.80) | |
| Return On Equity | (3.29) | (3.45) |
Things to note about Abeona Therapeutics performance evaluation
Checking the ongoing alerts about Abeona Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abeona Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abeona Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 3.5 M. Net Loss for the year was (54.19 M) with loss before overhead, payroll, taxes, and interest of (31.4 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (37.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Abeona Therapeutics Cut to Sell at StockNews.com |
- Analyzing Abeona Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abeona Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Abeona Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abeona Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abeona Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abeona Therapeutics' stock. These opinions can provide insight into Abeona Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.